Krish Patel, MD, Swedish Cancer Institute, Seattle, WA, presents results from the interim analysis of the ‘Watch’ Registry (NCT04545333), a multicenter observational study investigating the use of measurable residual disease (MRD) measurement with Clonoseq® in clinical practice for B-cell malignancies. Dr Patel highlights that the use of MRD in clinical practice varied among diseases, and was commonly used to assess prognosis in chronic lymphocytic leukemia (CLL), and guide treatment decisions in acute lymphoblastic leukemia (ALL). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.